Factors identified as giving rise to concern are the growing caution of the US Food and Drug Administration in the granting of marketing approval for new drugs which, in turn, put added pressure on the patent life, and the likelihood that genuine innovation will take a back seat behind drug modification and late-stage development. In addition to the findings of the survey, the report also highlights key issues relating to IP law and policy. For a copy of the report email Jo Colton here.
* 72 per cent of respondents believe that future drug pipelines will become much harder to deliver unless the drug approval process is relaxed;
* extensions to the existing patent term are advocated by 73 per cent of respondents;
* 91 per cent consider the time it now takes for drugs to get through the system is eating into patent protection;
* 78 per cent believe the climate for enabling biotechnology innovation has deteriorated within the past year.
One subject worthy of speculation and analysis is why the percentage of respondents who do not advocate an extension of the existing patent term stands at 27%. Is the divide between the pro- and anti-extension lobbies within the industry characterised by differences in national laws, industry sector, perceptions of the worth of new products in the corporate pipeline, job description ... or what?